On April 8, 2024 EpiBiologics, a preclinical stage company advancing new bispecific antibody therapeutics for extracellular protein degradation, reported the company is presenting data today on its EpiTAC protein degraders in oncology demonstrating robust in vivo anti-tumor activity and survival benefit (Press release, EpiBiologics, APR 8, 2024, View Source [SID1234643977]). EpiTAC bispecific antibodies leverage cell-surface degrader receptors enriched in disease tissue to selectively degrade membrane and extracellular targets and address significant unmet needs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We believe EpiTACs are a promising new modality, especially for difficult-to-drug targets," said Ann Lee-Karlon, Ph.D., President and CEO of EpiBiologics. "We’re committed to advancing EpiTACs for diverse targets in oncology and other disease areas."
These data are being presented this morning at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 in poster presentation #1866, "Discovery of mutation-independent EGFR degrading bispecific antibodies that suppress tumor growth in preclinical tumor models" with Jon Sitrin, Ph.D., Head of Translational Science for EpiBiologics as lead author.
Current cancer treatments targeting EGFR often yield limited benefits due to target-related toxicities and reduced effectiveness in patients with acquired resistance. Recognizing the importance of improving therapeutic outcomes, EpiBiologics tested the efficacy of its novel EpiTACS on this oncogenic driver.
"Our proof-of-concept data demonstrate that EpiTAC activity is greater than standard of care in multiple preclinical tumor models. EpiTAC degradation of EGFR is mutation-independent and can overcome resistance mechanisms. These data motivate us to develop new and clinically meaningful therapies," said Shyra Gardai, Ph.D., Chief Scientific Officer of EpiBiologics.
Poster Presentation Highlights
EpiTACs are bispecific antibodies with a target binding arm and degrader binding arm that together localize degradation of extracellular and membrane targets to disease tissue, sparing normal tissue and increasing efficacy
Novel EpiTACs were rapidly selected and tested using the EpiAtlas of 270+ tumor- and tissue-specific degraders, including transmembrane E3 ubiquitin ligases, chemokine/cytokine receptors and tissue-enriched internalizing receptors
EpiTACs drove robust in vitro tumoricidal activity in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) models, independent of KRAS or EGFR mutational status
In vivo tumor models demonstrated EpiTACs degraded mutant EGFR and disrupts downstream signaling, suppressing tumor growth and increasing survival beyond osimertinib standard of care
"We believe EpiTACs are a promising new modality, especially for difficult-to-drug targets," said Ann Lee-Karlon, Ph.D., President and CEO of EpiBiologics. "Our modular bispecific antibodies coupled with our EpiAtlas allow us to rapidly screen and manufacture EpiTACs that drive deep anti-tumor responses. We’re committed to advancing EpiTACs for diverse targets in oncology and other disease areas as we move quickly toward the clinic."